With psychedelics, mental health care may never be the same. All as some of the nation’s “top universities are racing to set up psychedelic research centers, and investors are pouring millions of dollars into a pack of start-ups. States and cities across the country are beginning to loosen restrictions on the drugs, the first steps in what some hope will lead to the federal decriminalization of psychedelics for therapeutic and even recreational use,” as reported by The New York Times. That’s been substantial news for NeonMind Biosciences (CSE:NEON) (OTC:NMDBF), Cybin Inc. (NEO:CYBN)(OTC:CLXPF), Tryp Therapeutics Inc. (CSE:TRYP), Mind Medicine Inc. (NEO:MMED)(OTC:MMEDF), and Compass Pathways (NASDAQ:CMPS).
Not only has the US FDA been supportive of psychedelics, Johns Hopkins, Yale, Berkeley, and Mount Sinai Hospital are establishing psychedelic divisions, as well. Plus, there’s been a substantial proof psychedelics can help with issues such as depression, anxiety, addiction, obsessive compulsive disorder, and obesity.
In fact, NeonMind Biosciences is exploring psilocybin as a potential treatment for obesity and to support weight loss. In fact, NeonMind’s first drug candidate employs psilocybin as an agonist to the serotonin receptor 5-HT2A, which is involved in the hallucinogenic effect of psychedelics. The second drug candidate employs psilocybin as an agonist to the serotonin 5-HT2C receptor, which controls appetite.
Read More